Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Official title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2024-10-21
Completion Date
2027-01
Last Updated
2025-09-26
Healthy Volunteers
No
Conditions
Interventions
Bimagrumab
Administered SC
Tirzepatide
Administered SC
Bimagrumab Placebo
Administered SC
Tirzepatide Placebo
Administered SC
Locations (12)
Pinnacle Research Group, LLC
Anniston, Alabama, United States
Central Research Associates
Birmingham, Alabama, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Jacksonville, Florida, United States
Altus Research
Lake Worth, Florida, United States
Suncoast Research Group
Miami, Florida, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, United States
SKY Integrative Medical Center/SKYCRNG
Ridgeland, Mississippi, United States
Keystone Clinical Studies
Plymouth Meeting, Pennsylvania, United States
Eastside Research Associates
Redmond, Washington, United States
Rainier Clinical Research Center
Renton, Washington, United States